Loading organizations...
Autolus has raised $137.0M across 2 funding rounds.
Key people at Autolus.
Autolus has raised $137.0M in total across 2 funding rounds.
Founded in 2014 by Martin Pule as a University College London spinout, Autolus Therapeutics is a clinical stage biopharmaceutical company based in London, England. With initial financial backing from founding investor Syncona, the organization develops advanced autologous CAR T cell therapies to treat severe hematological malignancies, solid tumors, and autoimmune diseases. The enterprise engineers patients' own immune cells using chimeric antigen receptors to precisely recognize, target, and attack difficult to treat cancers such as acute lymphoblastic leukemia. Operating as a publicly traded entity on the NASDAQ exchange with approximately 400 employees, the firm secured significant capital, including a $150 million initial public offering in 2018. In early 2024, Autolus received a $250 million strategic equity investment from BioNTech to advance its clinical pipeline and secured United States FDA approval for its obe-cel cell therapy.
Autolus has raised $137.0M in total across 2 funding rounds.
Autolus's investors include Accel, Accomplice VC, GV, Soffinova Partners, Stride VC, Ben Holmes, Joe Anderson, Bihua Chen, Nextech Invest, Martin Murphy, Woodford Investment Management.
Key people at Autolus.
Autolus is a clinical‑stage biotechnology company that engineers next‑generation CAR T (chimeric antigen receptor T‑cell) therapies to treat hematologic cancers, solid tumors and autoimmune diseases by applying modular “cell programming” to patient T cells to improve targeting, control and activity[2][1]. Autolus was spun out of University College London in 2014 around technology pioneered by Dr Martin Pule and has built integrated capabilities across R&D and manufacturing as it advances multiple clinical programs including its lead obe‑cel candidates[1][3].
High‑Level Overview
For the product/company view: Autolus builds autologous CAR‑T cell therapies by extracting a patient’s T cells, equipping them with engineered CARs and additional programming modules, and re‑infusing them; its customers are patients and treating physicians in oncology and immunology clinical settings, and the problem it aims to solve is limited efficacy, safety and control of first‑generation CAR‑T therapies—Autolus targets improved tumor recognition, activity and controllability[2][8]. Recent growth momentum includes a clinical‑stage pipeline with multiple programs (obe‑cel series and several AUTO programs), public listing and scaling of manufacturing and clinical operations[6][2].
Origin Story
Core Differentiators
Role in the Broader Tech/Life‑Sciences Landscape
Quick Take & Future Outlook
Quick take: Autolus is a UCL‑spun, clinical‑stage CAR‑T company focused on modular T‑cell programming and integrated manufacturing—its future hinges on clinical readouts for obe‑cel and other programs and its ability to scale controlled, cost‑effective autologous cell production[1][2][6].
Autolus has raised $137.0M across 2 funding rounds. Most recently, it raised $80.0M Series C in September 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2017 | $80M Series C | — | Accel, Accomplice VC, GV, Soffinova Partners, Stride VC, BEN Holmes, JOE Anderson, Bihua Chen, Nextech Invest, Martin Murphy, Woodford Investment Management | Announced |
| Mar 1, 2016 | $57M Series B | JOE Anderson, Woodford Investment Management | Soffinova Partners | Announced |